Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Trevor Angell

    TitleAssistant Professor of Clinical Medicine
    SchoolKeck School of Medicine of USC
    AddressBMT B11
    Off Campus
    Los Angeles California 90089-9113
    Phone+1 323 442 6179
    vCardDownload vCard
      Other Positions
      TitleAssociate Medical Director of Thyroid Center

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell T, Li Z, Epstein AL. Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models. Cancer Immunol Immunother. 2016 May; 65(5):511-23. PMID: 26960932; PMCID: PMC4841721 [Available on 05/01/17].
      2. Angell T, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016 Mar; 26(3):381-9. PMID: 26756227; PMCID: PMC4790214 [Available on 03/01/17].
      3. Angell T, Swaika A, Sood N, Goldfarb M, Siddiqi I, Ailawadhi S. Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge. Ann Hematol. 2015 Sep; 94(9):1603-4. PMID: 26048244.
        View in: PubMed
      4. Angell T, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. PMID: 25343237.
        View in: PubMed
      5. Angell T, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. PMID: 25294906; PMCID: PMC4252612.
      6. Angell T, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93. PMID: 24955518; PMCID: PMC4148060.
      7. Angell T, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014 Jul; 24(7):1127-33. PMID: 24697314.
        View in: PubMed
      8. Lechner MG, Karimi SS, Barry-Holson K, Angell T, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013 Nov-Dec; 36(9):477-89. PMID: 24145359; PMCID: PMC3910494.
      9. Lechner MG, Megiel C, Church CH, Angell T, Russell SM, Sevell RB, Jang JK, Brody GS, Epstein AL. Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma. Clin Cancer Res. 2012 Sep 01; 18(17):4549-59. PMID: 22791880.
        View in: PubMed